Current treatment options and strategies for myelodysplastic syndromes

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 10, 2008, Pages 1667-1678

  Srinivasan, Sridhar ^a   Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 azacytidine; Antithymocyte globulin; Decitabine; Lenalidomide; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMD 531; AMINOCAPROIC ACID; ANTHRACYCLINE DERIVATIVE; ANTIANEMIC AGENT; ANTIFIBRINOLYTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CYCLOSPORIN A; CYTARABINE; DEFERASIROX; DEFEROXAMINE; ERYTHROPOIETIN; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; LONAFARNIB; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PANOBINOSTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; REMIPLISTIM; RETINOIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLEEDING; BONE MARROW SUPPRESSION; BONE PAIN; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON CHELATION; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REMISSION; REVIEW; SCORING SYSTEM; SEDATION; SERUM SICKNESS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT PLANNING;

AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; ARSENICALS; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FARNESYLTRANSTRANSFERASE; HEMATINICS; HISTONE DEACETYLASES; HUMANS; IMMUNOLOGIC FACTORS; MYELODYSPLASTIC SYNDROMES; OXIDES; SOCIAL CLASS; STEM CELL TRANSPLANTATION;

EID: 48049104551     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.10.1667     Document Type: Review

References (91)

1. Greenberg P, editor. The myelodysplastic syndromes, hematology: basic principles and practice. 3rd edition. New York: Churchill Livingstone; 2000. p. 1106-29
2. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the united states. Cancer 2007;109:1536-42
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88
4. Schiffer CA. Clinical issues in the management of patients with myelodysplasia. Hematology Am Soc Hematol Educ Program 2006;205-10
5. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors, World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302
7. Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;91:1596-604
8. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10
9. Schiffer CA. World Health Organization and International Prognostic Scoring System: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Semin Hematol 2008;45:3-7
10. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006;81:104-30
11. Jabbour E, Kantarjian HM, Koller C, Taber A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-95
12. Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep 2003;2:122-9
13. Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003;121:270-4
14. Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 2006;106:2087-94
15. Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005;84:167-76
16. Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-7
17. Schuler U. Quality of life in patients with myelodysplastic syndromes. Cancer Treat Rev 2007;33(Suppl 1):S59-63
18. Jadersten M, Montgomery SM, Dybedal I, et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005;106:803-11
19. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46
20. Golshayan AR, Jin T, Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007;137:125-32
21. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 2008;111:574-82
22. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25
23. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO classification of MDS does make a difference. Blood 2004;103:3265-70
24. Miller KB, Haesook K, Greenberg P, et al. Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): results of the ECOG-CLSG trial (e1996) [abstracc #70]. Blood 2004;104
25. Jädersten M, Malcovati L, Dybedal I, et al. Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need [abstract #521]. Blood 2006;108
26. Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008 (in press)
27. Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12:1264-73
28. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-9
29. Malcovati I, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to who criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603
30. Chee CE, Steensma DP, Hanson CA, Tefferi A. Neither serum ferritin nor number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblast [abstract # 2454]. Blood 2007;110
31. Tefferi A: Iron chelation therapy for myelodysplastic syndrome: if and when. Mayo Clin Proc 2006;81:197-8
32. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-8
33. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62
34. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288-99
35. Greenberg P, Taylor K, Larson RL. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS) [abstract#196]. Blood 1993;82(Suppl)
36. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
37. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109:1705-14
38. Kantarjian H, Fenaux P, Sekeres M, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract #250]. Blood 2007;110
39. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-65
40. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57
41. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65
42. List A, Wride K, Dewald G. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leuk Res 2007;31:S38
43. Sekeres M, Maciejewski JP, Giagounidis A, et al. Cytopenias correlate with response to lenalidomide in del 5q mds patients. Leuk Res 2007;31:S37-8
44. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93
45. Melchert M, List A. Management of RBC-transfusion dependence. Hematology Am Soc Hematol Educ Program 2007;398-404
46. Melchert M, List A. Targeted therapies in myelodysplastic syndrome. Semin Hematol 2008;45:31-8
47. Burcheri S, Prebet T, Beyne-Rauzy O, et al. Lenalidomide (LEN) in INT 2 and high risk MDS with del 5q. Interim results of a phase II trial by the GFM [abstract #820]. Blood 2007;110
48. Melchert M, Williams C, List A. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome. Leukemia 2007;21:1576-8
49. Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007;21:586-8.
50. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002;137:156-63
51. Saunthararajah Y, Nakamura R, Nam JM, et al. Hla-dr15 (dr2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-4
52. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003;102:3025-7
53. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007;21:1436-41
54. Yazji S, Giles FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003;17:2101-6
55. Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004;18:460-5
56. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine a as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006;91:667-70
57. Sloand EM, Rezvani K: The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008;45:39-48
58. Steensma DP, Dispenzieri A, Moore SB, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003;101:2156-8
59. Sloand E, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008 In press
60. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract 2005;2(Suppl 1):S4-11
61. Shadduck RK, Latsko JM, Rossetti JM, et al. Recent advances in myelodysplastic syndromes. Exp Hematol 2007;35:137-43
62. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):21-9
63. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40
64. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-903
65. Lyons R, Cosgriff T, Modi S. Hematologic improvement, transfusion independence, and safety assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes [abstract #2662]. Blood 2006;108
66. Ward M, Stoltz ML, Etter JB, et al. An oral dosage formulation of azacitidine: a pilot pharmacokinetic study [abstract #7084]. J Clin Oncol 2007;25
67. Fenaux P, Mufti GJ, Finelli C, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study [abstract #817]. Blood 2007;110
68. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803
69. Kantarjian H, Garcia-Manero G, O'Brien S, et al. Survival and efficacy of decitabine in myelodysplastic syndromes (MDS), analysis of the 5-day iv dosing regimen [abstract #115]. Blood 2007;110
70. Steensma DP, Baer MR, Slack JL, et al. Preliminary results of a phase II study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome [abstract #1450]. Blood 2007;110
71. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-85
72. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836-46
73. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128-35
74. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993;82:677-81
75. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008;45:49-59
76. Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001;92:1999-2015
77. Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006;106:1099-109
78. Knipp S, Hildebrandt B, Giagounidis A, et al. Intensive chemotherapy is not recommended for patients with AML or high-risk MDS aged over 60 years with complex karyotype anomalies [abstract #72]. Blood 2004;104
79. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133-7
80. Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006;24:2456-64
81. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006;24:2465-71
82. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007;109:4158-63
83. Kurzrock R, Fenaux P, Rua A, et al. High-risk myelodysplastic syndrome (MDS): first results of international Phase 2 study with oral farnesyltransferase inhibitor r115777 (Zarnestra™) [abstract #68]. Blood 2004;104
84. Feldman EJ. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 2005;4:186-90
85. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-9
86. Soriano AO, Yang H, Faded S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-8
87. Garcia-Manero G: Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007;405-11
88. Nand S, Godwin J, Smith S, et al. Azacitidine plus gemtuzumab ozogamicin (GO): a novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly [abstract #1981]. Blood 2006;108
89. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of cd34+ cells in patients with the 5q- syndrome. Br J Haematol 2007;139:578-89
90. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335-9
91. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35